Quote:
Originally Posted by Betsy859
Seems like a long time to extend testing on already approved drugs if trials are positive. In the case of Nilotinib doses are much lower for PD patients. Not sure what hoops have to be jumped through to fast tract these approved drugs. First at least in the case of Nilotinib we have to wait for official published results and hope they compare to the unofficial results I was told. And I agree with ST that a lot can go wrong especially, in this case , the funding. STill I'm staying upbeat about this drug. I have to believe something out there is going to work for us to keep me going.
All the best to everyone.
|
It does seem like a long time. I was just comparing it to the FDA requirements for the more advanced trial of Isradipine, which is also approve; has been on the market much longer; and as a hypertension drug, is much safer than nilotinib, which is a chemotherapy drug.